Is ATYR or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Chemomab Therapeutics N/A -89.03% -79.68%

Which has stronger valuation and earnings, EDSA or CMMB?

Edesa Biotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.34 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is EDSA or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -437.50% -104.14% Chemomab Therapeutics N/A -89.03% -79.68%

Which has higher valuation and earnings, CMMB or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is CMMB or TIL more profitable?

Instil Bio's return on equity of -26.33% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Instil Bio N/A -26.33% -14.75%

Chemomab Therapeutics (CMMB) Competitors

$1.91 +0.01 (+0.53%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.90 0.00 (-0.26%)

As of 08/14/2026 04:19 PM Eastern

Compare

CMMB vs. ATYR, EDSA, TIL, TCRX, and MCRB

Should you buy Chemomab Therapeutics stock or one of its competitors? Chemomab Therapeutics's main competitors and comparable companies include aTyr Pharma (ATYR), Edesa Biotech (EDSA), Instil Bio (TIL), TScan Therapeutics (TCRX), and Seres Therapeutics (MCRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Chemomab Therapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

aTyr Pharma has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

In the previous week, aTyr Pharma had 14 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 15 mentions for aTyr Pharma and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat aTyr Pharma's score of 0.83 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
aTyr Pharma	Positive
Chemomab Therapeutics	Very Positive

Chemomab Therapeutics' return on equity of -89.03% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Chemomab Therapeutics has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	288.59	-$74.12M	-$0.62	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

aTyr Pharma currently has a consensus target price of $17.00, suggesting a potential upside of 2,941.14%. Chemomab Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 1,208.90%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

aTyr Pharma beats Chemomab Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Edesa Biotech had 6 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 7 mentions for Edesa Biotech and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat Edesa Biotech's score of 0.18 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Neutral
Chemomab Therapeutics	Very Positive

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Edesa Biotech currently has a consensus target price of $5.00, suggesting a potential downside of 6.54%. Chemomab Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 1,208.90%. Given Chemomab Therapeutics' higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edesa Biotech has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Edesa Biotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Chemomab Therapeutics' return on equity of -89.03% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-437.50%	-104.14%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Summary

Edesa Biotech beats Chemomab Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Instil Bio?

Chemomab Therapeutics (NASDAQ:CMMB) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Instil Bio's return on equity of -26.33% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Instil Bio	N/A	-26.33%	-14.75%

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Chemomab Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Chemomab Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 1,208.90%. Instil Bio has a consensus price target of $66.00, indicating a potential upside of 794.31%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Chemomab Therapeutics is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Instil Bio is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, Instil Bio had 2 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for Instil Bio and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat Instil Bio's score of -0.38 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Instil Bio	Neutral

Summary

Chemomab Therapeutics beats Instil Bio on 7 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to TScan Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Chemomab Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
TScan Therapeutics	$10.32M	4.93	-$129.77M	-$0.96	N/A

Chemomab Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. Chemomab Therapeutics' return on equity of -89.03% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Chemomab Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 1,208.90%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 670.42%. Given Chemomab Therapeutics' higher probable upside, research analysts clearly believe Chemomab Therapeutics is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Chemomab Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

In the previous week, TScan Therapeutics had 16 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 17 mentions for TScan Therapeutics and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat TScan Therapeutics' score of 0.48 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
TScan Therapeutics	Neutral

Summary

TScan Therapeutics beats Chemomab Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Seres Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Seres Therapeutics has higher revenue and earnings than Chemomab Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A

In the previous week, Seres Therapeutics had 2 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for Seres Therapeutics and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat Seres Therapeutics' score of 0.36 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Seres Therapeutics	Neutral

Chemomab Therapeutics presently has a consensus target price of $25.00, indicating a potential upside of 1,208.90%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 274.45%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Chemomab Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Chemomab Therapeutics' return on equity of -89.03% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Chemomab Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Chemomab Therapeutics beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.68M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.70%	2.57%	10.45%
P/E Ratio	-0.86	10.67	269.06	25.28
Price / Sales	N/A	1,275.04	592.96	87.71
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.96	16.78	12.91	6.24
Net Income	-$8.99M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-1.04%	1.74%	1.12%	1.07%
1 Month Performance	24.84%	1.60%	1.79%	1.03%
1 Year Performance	-46.78%	56.43%	67.69%	20.77%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	2.7101 of 5 stars	$1.91 +0.5%	$25.00 +1,208.9%	-46.8%	$13.68M	N/A	N/A	20	Positive News
ATYR aTyr Pharma	2.748 of 5 stars	$0.53 +1.0%	$17.00 +3,083.5%	-88.8%	$51.88M	$190K	N/A	53	Earnings Report Analyst Revision
EDSA Edesa Biotech	1.714 of 5 stars	$5.52 +5.3%	$5.00 -9.4%	+136.7%	$50.48M	N/A	N/A	20	News Coverage Earnings Report Gap Up
TIL Instil Bio	1.8281 of 5 stars	$7.49 +1.1%	$66.00 +781.2%	-73.9%	$50.25M	N/A	N/A	410	News Coverage Positive News Earnings Report
TCRX TScan Therapeutics	3.5435 of 5 stars	$0.78 +1.3%	$6.00 +672.4%	-57.0%	$50.12M	$10.32M	N/A	100	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. ATYR, EDSA, TIL, TCRX, and MCRB

How does Chemomab Therapeutics compare to aTyr Pharma?

Summary

How does Chemomab Therapeutics compare to Edesa Biotech?

Summary

How does Chemomab Therapeutics compare to Instil Bio?

Summary

How does Chemomab Therapeutics compare to TScan Therapeutics?

Summary

How does Chemomab Therapeutics compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. ATYR, EDSA, TIL, TCRX, and MCRB

How does Chemomab Therapeutics compare to aTyr Pharma?

Do insiders and institutionals hold more shares of ATYR or CMMB?

Which has more volatility and risk, ATYR or CMMB?

Does the media refer more to ATYR or CMMB?

Is ATYR or CMMB more profitable?

Which has higher valuation & earnings, ATYR or CMMB?

Do analysts rate ATYR or CMMB?

Summary

How does Chemomab Therapeutics compare to Edesa Biotech?

Does the media prefer EDSA or CMMB?

Do institutionals and insiders hold more shares of EDSA or CMMB?

Do analysts rate EDSA or CMMB?

Which has more volatility & risk, EDSA or CMMB?

Which has stronger valuation and earnings, EDSA or CMMB?

Is EDSA or CMMB more profitable?

Summary

How does Chemomab Therapeutics compare to Instil Bio?

Is CMMB or TIL more profitable?

Do insiders & institutionals have more ownership in CMMB or TIL?

Which has more volatility and risk, CMMB or TIL?

Do analysts rate CMMB or TIL?

Which has higher valuation and earnings, CMMB or TIL?

Does the media prefer CMMB or TIL?

Summary

How does Chemomab Therapeutics compare to TScan Therapeutics?

Which has preferable earnings & valuation, CMMB or TCRX?

Is CMMB or TCRX more profitable?

Do institutionals and insiders have more ownership in CMMB or TCRX?

Do analysts rate CMMB or TCRX?

Which has more volatility & risk, CMMB or TCRX?

Does the media prefer CMMB or TCRX?

Summary

How does Chemomab Therapeutics compare to Seres Therapeutics?

Which has stronger valuation & earnings, CMMB or MCRB?

Does the media prefer CMMB or MCRB?

Do analysts recommend CMMB or MCRB?

Is CMMB or MCRB more profitable?

Which has more risk and volatility, CMMB or MCRB?

Do institutionals & insiders have more ownership in CMMB or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools